5:50 PM
 | 
Nov 05, 2013
 |  BC Extra  |  Financial News

'Celebrity publicity' bolsters Myriad sales

Myriad Genetics Inc. (NASDAQ:MYGN) reported earnings for its fiscal 1Q ended Sept. 30 that beat the Street, including a $35 million one-time bump in revenues that the company attributed to "celebrity publicity" in mid-May. In May, The New York Times ran an...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >